• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人群建模突出了替诺福韦艾拉酚胺和富马酸替诺福韦二吡呋酯在血液和精液中药物处置的差异。

Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.

机构信息

University of North Carolina (UNC), UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

SK Life Science, Inc, Fair Lawn, New Jersey, USA.

出版信息

Clin Pharmacol Ther. 2019 Oct;106(4):821-830. doi: 10.1002/cpt.1464. Epub 2019 May 31.

DOI:10.1002/cpt.1464
PMID:31002391
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7079728/
Abstract

Understanding antiretroviral disposition in the male genital tract, a distinct viral compartment, can provide insight for the eradication of HIV. Population pharmacokinetic modeling was conducted to investigate the disposition of tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and emtricitabine and their metabolites in blood and semen. Blood plasma and seminal plasma (SP) concentrations of tenofovir and emtricitabine were measured, as were tenofovir-diphosphate and emtricitabine-triphosphate concentrations in peripheral blood mononuclear cells (PBMCs) and seminal mononuclear cells. Sequential compartmental modeling described drug disposition in blood and semen. Our modeling suggests slower elimination of apparent tenofovir-diphosphate PBMC and faster elimination of tenofovir SP after administration of TAF compared with TDF, likely reflecting flip-flop kinetics. Additionally, TAF metabolism to tenofovir appeared slower in semen compared with blood; however, SP elimination of TAF-derived tenofovir appeared faster than its blood plasma elimination. These findings provide valuable insight for further mechanistic study of cellular entry and drug metabolism in the male genital tract.

摘要

了解男性生殖道(一个独特的病毒隔室)中的抗逆转录病毒处置情况,可以为 HIV 的根除提供深入了解。进行了群体药代动力学建模,以研究富马酸替诺福韦二吡呋酯(TDF)、替诺福韦艾拉酚胺(TAF)和恩曲他滨及其代谢物在血液和精液中的处置情况。测量了替诺福韦和恩曲他滨在血浆和精液中的浓度,以及外周血单核细胞(PBMC)和精单核细胞中替诺福韦二磷酸和恩曲他滨三磷酸的浓度。顺序隔室建模描述了药物在血液和精液中的处置情况。我们的模型表明,与 TDF 相比,TAF 给药后 PBMC 中表观替诺福韦二磷酸的消除更慢,而 SP 中替诺福韦的消除更快,这可能反映了翻转动力学。此外,与血液相比,TAF 在精液中的代谢似乎更慢;然而,SP 中 TAF 衍生的替诺福韦的消除速度似乎快于其血浆消除速度。这些发现为进一步研究男性生殖道中的细胞进入和药物代谢的机制提供了有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ce6/7079728/5bd86002bcd0/nihms-1552535-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ce6/7079728/940d9d9f40cd/nihms-1552535-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ce6/7079728/a3558578ee1b/nihms-1552535-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ce6/7079728/5bd86002bcd0/nihms-1552535-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ce6/7079728/940d9d9f40cd/nihms-1552535-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ce6/7079728/a3558578ee1b/nihms-1552535-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ce6/7079728/5bd86002bcd0/nihms-1552535-f0003.jpg

相似文献

1
Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen.人群建模突出了替诺福韦艾拉酚胺和富马酸替诺福韦二吡呋酯在血液和精液中药物处置的差异。
Clin Pharmacol Ther. 2019 Oct;106(4):821-830. doi: 10.1002/cpt.1464. Epub 2019 May 31.
2
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).与替诺福韦酯相比,丙酚替诺福韦的精液替诺福韦浓度、病毒抑制及精液质量(西班牙HIV/AIDS研究网络,PreEC/RIS 40)
Clin Infect Dis. 2019 Sep 27;69(8):1403-1409. doi: 10.1093/cid/ciy1074.
3
Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.两种替诺福韦制剂在男性生殖道中的细胞外分布不同,但细胞内分布相似。
Antivir Ther. 2019;24(1):45-50. doi: 10.3851/IMP3277.
4
The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.富马酸替诺福韦二吡呋酯和替诺福韦艾拉酚胺在感染 HIV 人群中的淋巴组织药代动力学。
Clin Pharmacol Ther. 2020 Nov;108(5):971-975. doi: 10.1002/cpt.1883. Epub 2020 Jun 11.
5
Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.替诺福韦酯转换为替诺福韦艾拉酚胺的患者体内血浆和细胞内药代动力学。
AIDS. 2018 Mar 27;32(6):761-765. doi: 10.1097/QAD.0000000000001744.
6
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.在初治的HIV-1感染受试者中,使用埃替格韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺或埃替格韦/考比司他/恩曲他滨/替诺福韦酯进行96周治疗后耐药性出现频率较低。
Antivir Ther. 2017;22(5):443-446. doi: 10.3851/IMP3125. Epub 2017 Jan 11.
7
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.多替拉韦加拉米夫定与恩曲他滨和丙酚替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯对比依非韦伦、恩曲他滨和富马酸替诺福韦二吡呋酯,用于治疗人类免疫缺陷病毒 1 型感染的初始治疗(ADVANCE):一项随机、3 期、非劣效性试验的第 96 周结果。
Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1.
8
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.从依非韦伦、恩曲他滨和富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺与利匹韦林和恩曲他滨联合复方制剂用于治疗 HIV-1 感染病毒抑制成人:一项随机、双盲、多中心、3b 期、非劣效性研究。
Lancet HIV. 2017 May;4(5):e205-e213. doi: 10.1016/S2352-3018(17)30032-2. Epub 2017 Mar 2.
9
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺与利匹韦林和恩曲他滨固定剂量复方制剂用于病毒学抑制的 HIV-1 感染成人:一项随机、双盲、多中心、3b 期、非劣效性研究。
Lancet HIV. 2017 May;4(5):e195-e204. doi: 10.1016/S2352-3018(17)30031-0. Epub 2017 Mar 2.
10
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.替诺福韦艾拉酚胺 10 天单药治疗 HIV-1 阳性成人的抗病毒活性、安全性和药代动力学/药效学。
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55. doi: 10.1097/QAI.0b013e3182965d45.

引用本文的文献

1
Application of a Physiologically Based Pharmacokinetic Approach to Predict Tenofovir Pharmacokinetics During Pregnancy.应用基于生理的药代动力学方法预测孕期替诺福韦的药代动力学。
AAPS J. 2025 Feb 12;27(1):43. doi: 10.1208/s12248-025-01031-y.
2
Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring.建立并验证一种超高效液相色谱-串联质谱法,用于定量人血浆中的抗逆转录病毒药物浓度,以进行治疗药物监测。
J Pharm Biomed Anal. 2024 Mar 15;240:115932. doi: 10.1016/j.jpba.2023.115932. Epub 2023 Dec 30.
3

本文引用的文献

1
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).与替诺福韦酯相比,丙酚替诺福韦的精液替诺福韦浓度、病毒抑制及精液质量(西班牙HIV/AIDS研究网络,PreEC/RIS 40)
Clin Infect Dis. 2019 Sep 27;69(8):1403-1409. doi: 10.1093/cid/ciy1074.
2
Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.两种替诺福韦制剂在男性生殖道中的细胞外分布不同,但细胞内分布相似。
Antivir Ther. 2019;24(1):45-50. doi: 10.3851/IMP3277.
3
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention.
用于艾滋病毒预防的替诺福韦和恩曲他滨粘膜组织浓度的多隔室群体 PK 模型。
CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1922-1930. doi: 10.1002/psp4.13042. Epub 2023 Oct 9.
4
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.人群药代动力学模型研究慢性肾脏病对替诺福韦艾拉酚胺给药后替诺福韦暴露的影响。
J Antimicrob Chemother. 2023 Jun 1;78(6):1433-1443. doi: 10.1093/jac/dkad103.
5
Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population.在非洲人群中,以富马酸替诺福韦二吡呋酯或替诺福韦艾拉酚胺形式给予替诺福韦的群体药代动力学。
CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):821-830. doi: 10.1002/psp4.12955. Epub 2023 Apr 4.
6
A Novel Algorithm to Improve PrEP Adherence Monitoring Using Dried Blood Spots.一种利用干血斑提高 PrEP 依从性监测的新算法。
Clin Pharmacol Ther. 2023 Apr;113(4):896-903. doi: 10.1002/cpt.2845. Epub 2023 Jan 31.
7
Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.跨性别女性中替诺福韦、恩曲他滨和细胞内代谢物的群体药代动力学。
Br J Clin Pharmacol. 2022 Aug;88(8):3674-3682. doi: 10.1111/bcp.15310. Epub 2022 Mar 25.
8
Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.富马酸替诺福韦二吡呋酯在妊娠和产后妇女中应用的群体药代动力学研究。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02168-20.
9
Tenofovir alafenamide use in pregnant and lactating women living with HIV.替诺福韦艾拉酚胺在感染HIV的孕妇和哺乳期妇女中的应用。
Expert Opin Drug Metab Toxicol. 2020 Apr;16(4):333-342. doi: 10.1080/17425255.2020.1738384. Epub 2020 Mar 17.
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
一种用于预测针对注射吸毒人群的有效 HIV 预防给药策略的药代动力学/药效学模型。
J Pharmacol Exp Ther. 2018 Nov;367(2):245-251. doi: 10.1124/jpet.118.251009. Epub 2018 Aug 27.
4
The role of latency reversal agents in the cure of HIV: A review of current data.潜伏逆转剂在 HIV 治愈中的作用:对现有数据的综述。
Immunol Lett. 2018 Apr;196:135-139. doi: 10.1016/j.imlet.2018.02.004. Epub 2018 Feb 7.
5
Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.替诺福韦酯转换为替诺福韦艾拉酚胺的患者体内血浆和细胞内药代动力学。
AIDS. 2018 Mar 27;32(6):761-765. doi: 10.1097/QAD.0000000000001744.
6
Barriers to HIV Cure.HIV 治愈障碍。
HLA. 2016 Oct;88(4):155-63. doi: 10.1111/tan.12867.
7
HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.开始首个抗逆转录病毒治疗方案的患者精液中的HIV-1-RNA衰变与多替拉韦浓度
J Infect Dis. 2016 Nov 15;214(10):1512-1519. doi: 10.1093/infdis/jiw406. Epub 2016 Aug 30.
8
Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.替诺福韦在血清学不一致夫妇中未感染HIV-1成员体内的群体药代动力学及剂量报告方法的影响。
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5379-86. doi: 10.1128/AAC.00559-16. Print 2016 Sep.
9
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.替诺福韦艾拉酚胺在重度肾功能损害的未感染HIV受试者中的药代动力学和安全性
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5135-40. doi: 10.1128/AAC.00005-16. Print 2016 Sep.
10
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.一种转化药理学方法,用于预测使用富马酸替诺福韦二吡呋酯联合或不联合恩曲他滨对男性和女性进行暴露前预防艾滋病毒的结果。
J Infect Dis. 2016 Jul 1;214(1):55-64. doi: 10.1093/infdis/jiw077. Epub 2016 Feb 24.